SCHEMBL24596284

SCHEMBL24596284

FC(F)(F)c1ccc(Br)c(Nc2ccccc2Cl)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 4/20 0.54
CDK19 Q9BWU1 1/20 0.42
ALK Q9UM73 1/20 0.42
TSHR P16473 2/20 0.41
AURKA O14965 2/20 0.41
AURKB Q96GD4 1/20 0.41
PDE5A O76074 1/20 0.40
MAT2A P31153 2/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CDK2 P24941 1/20 0.39
ADRA2A P08913 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
PTK2 Q05397 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
KMT2A Q03164 1/20 0.37
KDM4E B2RXH2 1/20 0.37
HSD17B10 Q99714 1/20 0.37
LCK P06239 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596400 0.89 IGF1R (0.42) IGF1RAURKBMAT2ACDK2TRPV1
SCHEMBL24596297 0.84 EPHX2 (0.47) TSHRAURKAKMT2AKDM4E
SCHEMBL24596390 0.84 LMNA (0.45) IGF1RTSHRAURKAPTK2KMT2A
SCHEMBL24596403 0.83 KDM4E (0.47) IGF1RTSHRKDM4EHSD17B10
SCHEMBL24596182 0.82 CCR4 (0.40) AURKATRPV1KMT2AHDAC4HDAC6
SCHEMBL24596360 0.82 LMNA (0.36) IGF1RTSHRAURKAAURKB
SCHEMBL24596261 0.82 IGF1R (0.35) IGF1RTSHRADRA2AKMT2AKDM4E
SCHEMBL24596185 0.82 ALOX15 (0.38) IGF1RTSHRAURKAKMT2AKDM4E
SCHEMBL24596254 0.81 ENPP3 (0.35) IGF1RMAT2A
SCHEMBL24122511 0.79 TSHR (0.46) IGF1RTSHRAURKAAURKBPDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A IGF1R 4239/4885CDK19 2836/4885ALK 4774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.